Recent Advance in Drug Development of Squamous Cell Carcinoma

• Published in: Anti-cancer agents in medicinal chemistry Vol. 15; no. 7; p. 816
• Main Authors: Lei, Jun, Fu, Bing, Yin, Hang, Tang, Guanxiu, Zhu, Shujuan, Yan, Chunli, He, Quanyong
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2015
• Subjects: Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - metabolism; DNA-Directed RNA Polymerases - antagonists & inhibitors; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - metabolism; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - metabolism; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Mitogen-Activated Protein Kinase 14 - antagonists & inhibitors; Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptors, CXCR - antagonists & inhibitors; Toll-Like Receptors - agonists
• ISSN: 1875-5992
• DOI: 10.2174/1871520615666150113103938

Squamous cell carcinoma (SCC) has a high worldwide incidence that is commonly seen as head and neck cancers, esophageal cancers, and non-small cell lung cancers. There is a poor prognosis for SCC due to potential recurrence and its metastatic tendency so the 5-year survival rate is very low. Target therapy is a novel and promising treatment strategy exhibiting great anti-tumor effects and survival benefits in SCC. This review summarizes current treatment strategies from clinical and experimental studies, including the agents targeting epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, CXCR, and the related combination therapy regimens. However, there are still many challenges we have to face. It is a burning need to improve the development and availability of drug formulations.